HOOKIPA Pharma Announces Publication of HB-101 Phase 1 Results in The Journal of Infectious Diseases
HOOKIPA Pharma Inc. (HOOK)
Last hookipa pharma inc. earnings: 3/19 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
NEW YORK and VIENNA, Austria, April 21, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced the publication in The Journal of Infectious Diseases of the Phase 1 results of HOOKIPA's VaxWave®-based prophylactic Cytomegalovirus (CMV) vaccine candidate HB-101, which is currently in a Phase 2 clinical trial. The paper concludes that HB-101 was well tolerated and induced CMV-specific poly-functional CD8 T cell and neutralizing antibody responses in nearly all subjects. The absence of vector-neutralizing antibody responses allowed all CMV antigen-specific immune responses to be increased in a statistically significant manner upon repeated vaccine re-administration, which should facilitate additional booster vaccinations. Hence, HOOKIPA's vaccine candidate holds promise for prevention of clinically signific
Show less
Read more
Impact Snapshot
Event Time:
HOOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOOK alerts
High impacting HOOKIPA Pharma Inc. news events
Weekly update
A roundup of the hottest topics
HOOK
News
- Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at JMP Securities from $24.00 to $7.00. They now have a "market outperform" rating on the stock.MarketBeat
- Hookipa Pharma Inc (NASDAQ: HOOK) had its price target lowered by analysts at Royal Bank of Canada from $50.00 to $48.00. They now have an "outperform" rating on the stock.MarketBeat
- HOOKIPA Pharma GAAP EPS of -$1.10, revenue of $4.7M [Seeking Alpha]Seeking Alpha
- HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates [Yahoo! Finance]Yahoo! Finance
- HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business UpdatesGlobeNewswire
HOOK
Earnings
- 8/8/24 - Miss
HOOK
Sec Filings
- 11/20/24 - Form 8-K
- 11/14/24 - Form SC
- 11/14/24 - Form 10-Q
- HOOK's page on the SEC website